At a Glance
- Company: Novo Nordisk A/S
- Location: Bagsværd, Denmark (US focus)
- Headline figures: Wegovy to $675/mo (-50%); Ozempic -35%
- Focus area: Self-pay Wegovy/Ozempic demand
- Next steps: Pricing effective Jan 2027; Rybelsus included
What happened?
Novo Nordisk announced on 24 February 2026 plans to cut US list prices for Wegovy by up to 50% and Ozempic by 35%, effective January 2027. Both flagship GLP-1s will standardise at $675 per month, including oral Rybelsus, responding to booming self-pay demand outside insurance coverage.
Why does it matter?
Wegovy/Ozempic list prices exceed $1,300 monthly, but self-pay volumes surge as insurers restrict obesity coverage; cuts align cash pricing with Medicare negotiations ($274/mo from 2027) and compete with compounded versions. Move supports access amid 20M+ US users while protecting margins via volume growth.
Who’s behind it?
Novo Nordisk dominates GLP-1s with >$20B 2025 sales; cuts follow Trump-era deals, cash-pay initiatives ($349/mo since Nov 2025) and competition from Lilly’s Zepbound.
How was it achieved?
Pricing reflects direct-to-consumer shifts (Novocare.com) and Medicare Inflation Reduction Act caps, timed for 2027 rollout. Applies across doses/formulations, excluding highest Ozempic (2mg).
What’s next?
Implementation January 2027 alongside Medicare pricing; expand telehealth/retail partnerships. Analysts expect low-single-digit sales growth impact offset by volumes.
What are people saying?
Novo: “Improving affordability… in changing US landscape.” Analysts note “manageable” amid competition.